Menu
1 min read · estimated
APPROVED USE
What FDA approved
An alternative 1,500 mg every four weeks schedule for patients weighing at least 30 kg with unresectable stage III non-small cell lung cancer or the then-approved urothelial carcinoma indication.
LAMPGEN ANALYSIS
Why it matters
Offered a longer infusion interval for two existing indications; the U.S. urothelial carcinoma indication was later withdrawn.
What research teams should watch
Keep infusion schedules and labeled disease status distinct, and verify applicable weight-based dosing rules.
PRIMARY RECORDS